Listed are still awaiting approval of cervical cancer vaccine
Developed cervical cancer vaccine is the first human cancer vaccine. Following the Merck company, another pharmaceutical giant GlaxoSmithKline has launched its cervical cancer vaccine. And cervical cancer, has become a human can be prevented and uniforms the first malignancy. However, the cervical cancer vaccine market in China, so Chinese women benefit, still need to undergo a rigorous approval process, but high vaccination costs, the popularity of the vaccine will also be affected.
"We finally determined through the meta-analysis of the advantages of Chinese women in the HPV type," the Institute of Chinese Academy of Medical Sciences, Professor Qiao Youlin excitedly told reporters, "We found that HPV16 and HPV18 are two advantages in addition to HPV types, HPV58 lead to cervical cancer in Chinese women is the third major advantage of HPV types. " Professor Joe
Dr. Bao Yanping students began a year ago, the 18 project sites for women in the prevalence of HPV types investigated, tried in the past 18 separate research projects of integrated analysis, find out Chinese women's cervical cancer led to a major HPV types.
The 18 research projects for the national 10 provinces and cities, these ten cities are: Shanghai, Jiangxi, Hunan, Sichuan, Guangdong, Beijing, Liaoning, Inner Mongolia, Shanxi and Shaanxi.
The 18 independent study using PCR to detect HPV types of cervical neoplasia in three types of cervical cancer cases in the infection rate. [The three types of cervical cancer are: invasive cervical cancer (ICC), a high degree of cervical intraepithelial neoplasia (HSIL), low-grade cervical intraepithelial neoplasia (LSIL)].
By various HPV infection rates in neoplasia in the analysis showed that the HPV16 and HPV18 infection in cervical cancer type by the proportion of total cervical cancer types of 69.6%.
"HPV16 and HPV18 is the world's two most common cancer type," said Professor Joe, "is now facing the United States, GlaxoSmithKline and Merck have been produced for These two HPV types other vaccines. " According to the British "Times" recently reported that the pharmaceutical giant GlaxoSmithKline has produced a well-known as the "Cer-varix" of the cervical cancer vaccine, this vaccine has been shown to be effective in preventing female human papillomavirus (HPV) are two strains ?? HPV16 and HPV18. "Cer-varix" in May this year has been on the market in Australia.
Another pharmaceutical giant Merck has also produced "Gardasil" cervical cancer vaccine, and in June 2006 by the U.S. Food and Drug Administration (FDA) approval, already in Europe and the United States and the Asia Pacific region nearly 80 countries listed nearly a year.
These two vaccines against HPV16 and HPV18 have 100% prevention. But at this stage there is still 30.4% of pathogenic strains of HPV cervical cancer without any effective countermeasures. According to the report, Professor Joe found that, in addition to HPV16 and HPV18, HPV58 is the advantage of Chinese women in the HPV type. There is no specific HPV58 of vaccines.
"Cer-varix" in resisting the invasion of HPV16 and HPV18 HPV31 and HPV45 while resistance to two cancer-causing strain of the virus; "Gardasil" in the fight against HPV16 and HPV18, it is also against HPV6 and HPV11, which two virus strains that cause genital warts important viruses, therefore, men can also be injected with "Gardasil".
Two companies currently have in 2006 presented to the Chinese Food and Drug Administration applications for registration, currently in the approval stage.
"From the cervical cancer vaccine market in China may take a long time," Professor Joe explains: "Most of the vaccine is actually a virus, make the body produce antibodies, but there will be the risk of infection, therefore, SFDA in the vaccine given to foreign registered on a stringent approval process. Although the 'Cer-varix' and 'Gardasil' is the HPV virus-like particles, with similar to the natural structure of the virus does not contain DNA, not the real virus, it will not trigger the body as a result of vaccine virus infection, but still have to go through the normal SFDA approval process. "
The same time, after clinical trials after approval will last for a long period of time. China Cancer Research Foundation of Dong Zhiwei, vice chairman, said the Chinese drug regulators in the normal population for clinical trials with caution.
As for the Chinese market when it appears "Cer-varix" or "Gardasil", we wait and see.
I am Cheap On Sales writer, reports some information about fish pond equipment , wood dog kennel.
Processing your request, Please wait....
